University of Colorado

Alcon, Inc.

Alcon Research, Ltd.

Spyglass Pharma, Inc.

Alcon Manufacturing, Ltd.

Allergan, Inc.

Alcon Laboratories, Inc.

Novartis Ag

Clarvista Medical, Inc.

Other

Advanced Medical Optics, Inc.

Glenn R Sussman

Malik Y Kahook

Donald M Cohen

Paul McLean

Craig Alan Cable, Ii

John Morgan Bourne

Andrew T Schieber

Guangyao Jia

Martin J Padget

James R Dennewill

Robert E Atkinson

Rudolph F Zacher

Crystal M Cunanan

Sean Christopher Madden

Thomas G Capetan

Craig Young

Naresh Mandava

Robert J Cionni

Ziad R Ghannoum

Harvey Uy

Kerry Solomon

Ramon C Dimalanta

Mikhail Boukhny

Bernard F Grisoni

Jim Deacon

Joseph I Weinschenk, Iii

John R Underwood

Ann Yadlowsky

Ahmad Salehi

John Richard Carpenter

Lawrence W Darnell

Sean Maass

Ryan Absalonson

Paul Mclean

Steven Thomas Charles

Gary P Sorensen

Jason H Safabash

Mandar V Shah

Edward R Zaleski

Uday Doshi

Kerry L Markwardt

Amir H Khashayar

Don A Clements

Paul J McLEAN

Hsin S Chin

Daniel J Kao

Andrew Thomas Schieber

Craig Alan Cable Ii

Embodiments disclosed herein generally relate to an intraocular drug delivery system configured for implantation into an eye of a subject. The intraocular drug delivery system can include an intraocular lens (IOL) and a drug delivery component. The IOL includes an anterior side, a posterior side opposite the anterior side, a lens bordered by an edge and a haptic extending outwardly from the edge of the lens at a lens-haptic junction. The haptic includes, at the lens-haptic junction, a relief cut on the posterior side of the IOL. The drug delivery component includes a therapeutic agent and a fixation portion having an opening configured to receive the haptic therethrough. The fixation portion is configured to be secured to the relief cut of the haptic such that outward movement of the drug delivery component relative to the lens is inhibited.

Stabilized intraocular drug delivery systems and methods of use

Modular IOL systems including a base and a lens, wherein the lens includes fixed and actuatable tabs for connection to the base. The modular IOL allows for the lens to be adjusted or exchanged while leaving the base in place, either intra-operatively or post-operatively. Drug delivery capabilities and/or sensing capabilities may be incorporated into the base. Injector devices may be used to facilitate placement of the base and the lens sequentially or simultaneously into the eye.

Modular intraocular lens designs, tools and methods

Embodiments of the instant disclosure relate to intraocular drug delivery devices for and methods of, delivering at least one therapeutic agent to an eye of a subject. Methods include implanting an intraocular implant into the eye and adjacent to a fluid-permeable membrane of the eye of the patient. Intraocular implants are supported in a position at a surface of the fluid-permeable membrane. Intraocular implants include a drug delivery component having at least one therapeutic agent embedded within a non-bioerodible, non-biodegradable polymer matrix. Devices and methods disclosed herein can further include delivering the at least one therapeutic agent to the eye of the subject according to a near zero-order elution rate of the at least one therapeutic agent.

Intraocular drug delivery systems and methods of use

An intraocular drug delivery platform including a ring having an anterior surface and a posterior surface opposite the anterior surface, a central aperture formed by the ring, a first haptic coupled to and extending outwards from the ring, a second haptic coupled to and extending outwards from the ring, a first drug eluting mass operably coupled to the anterior surface of the ring, and a second drug eluting mass operably coupled to the anterior surface of the ring and positioned directly opposite of the first drug eluting mass.

Intraocular drug delivery platform

Modular IOL systems including a base and a lens, wherein the lens includes tabs for connection to the base. The modular IOL allows for the lens to be adjusted or exchanged while leaving the base in place, either intra-operatively or post-operatively.

An ophthalmic implant including an intraocular lens (IOL) and at least one drug delivery device. The IOL including an anterior side, a posterior side, a lens, and at least one haptic extending outwardly from the lens and including a first haptic extending from the lens at a first optic-haptic junction. The at least one drug delivery device including a first drug delivery device including a pad and a fixation portion extending from the pad. The pad including at least one therapeutic agent contained therein, an anterior surface, a posterior surface, and a sidewall extending around the pad and between the anterior surface and the posterior surface. The drug delivery device configured for attachment to the IOL via the fixation portion. In an assembled state of the implant, the first drug delivery device is attached to the IOL and the pad overlays the first optic-haptic junction.

Ophthalmic implant system for drug delivery

An ophthalmic implant including an IOL with haptics, and drug delivery devices secured to the haptics. The posterior-most extent of the drug delivery device is located anterior to the posterior edge or PCE barrier edge, of the IOL. In other configurations, the drug delivery devices are provided with PCO barrier edges.

IOL with drug delivery devices and uninterrupted PCO barrier edge

An intraocular drug delivery platform for use with an intraocular lens assembly. The platform includes a ring and haptics to maintain the ring in position in the capsular bag, compartments on the anterior surface of the ring for accommodating a drug eluting matrix or other drug mass, and a skirt extending posteriorly from the posterior surface of the ring to constrain movement, including lateral or inferior/superior movement, of the intraocular lens relative to the ring.

This disclosure provides ophthalmic implants such as sulcus implants which can comprise one or more drug delivery devices. Further provided herein are methods of using the drug delivery ophthalmic devices described herein for implantation into a subject's eye, e.g., into an eye's ciliary sulcus or capsular bag.

Sulcus implants and methods of using the same

Embodiments disclosed herein generally relate to a stabilized intraocular drug delivery system for implantation into an eye of a subject. The system can include an intraocular lens (IOL) assembly and a drug delivery component. The IOL assembly can include a lens and a haptic. The haptic can include an outer end, an inner end opposite the outer end, a retention tab at the inner end, and a connection tab positioned between the outer end and the inner end and adjoining the lens. The drug delivery component can include at least one therapeutic agent and a fixation portion having an opening to receive the haptic and secure the drug delivery component to the IOL assembly. The fixation portion of the drug delivery component can be secured to the connection tab of the haptic such that the retention tab inhibits movement of the drug delivery component relative to the IOL assembly.

An ophthalmic implant configured for peri-operative, intra-operative, or post-operative assembly and disassembly. Drug delivery devices may be implanted with an intraocular lens, and later removed and replaced with new drug delivery devices.

Modular IOL removal systems and methods that cut an optic portion of an intraocular in a single motion such to facilitate removal of the optic portion from an eye through an incision, for example a corneal incision, without increasing the size of the corneal incision. Various cutting tools having one or more blades may be utilized. The cut intraocular lens may have one continuous cut or be cut into multiple smaller pieces. The single cutting step may apply balanced forces and torque to avoid damaging the surrounding eye anatomy, reducing the risk of trauma.

A modular IOL system including intraocular primary and secondary components, which, when combined, form an intraocular optical correction device, wherein the secondary component is placed on the primary component within the perimeter of the capsulorhexis, thus avoiding the need to touch or otherwise manipulate the capsular bag. The secondary component may be manipulated, removed, and/or exchanged for a different secondary component for correction or modification of the optical result, on an intra-operative or post-operative basis, without the need to remove the primary component and without the need to manipulate the capsular bag. The primary component may have haptics extending therefrom for centration in the capsular bag, and the secondary component may exclude haptics, relying instead on attachment to the primary component for stability. Such attachment may include actuatable interlocking members.

Modular intraocular lens designs and methods

Growing community of inventors

Lake Forest, CA, United States of America

Glenn R Sussman